{
  "trial_id": "NCT02311543",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "at registration",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patient has given written informed consent before registration",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Female patients; eligible for primary ALND or sentinel lymph node procedure with frozen section and either: newly diagnosed or recurrent breast cancer in the conserved breast, chest wall or axilla",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patients with histo- or cytology proven breast cancer UICC/AJCC stage I-III",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Age \u2265 18 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Fluency in either German, French, Italian, Spanish, Turkish or English",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "The EQ-5D questionnaire has been completed at registration",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patient with child-bearing potential, willing to use effective contraception, not currently pregnant and agreeing not to become pregnant after trial registration and during the 24 weeks after surgery",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "with child-bearing potential",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "ALND indicated according to clinical standards, either as single procedure or in combination with breast conserving surgery",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Known hypersensitivity for TachoSil\u00ae or fibrin sealant",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patients with mastectomy (simultaneously or within 1 month before registration); patients undergoing completion mastectomy at a later day will remain eligible and are evaluable for analysis according to intention to treat. If the axillary drain is still in place at the time of completion mastectomy and a separate drain is inserted underneath the skin flaps, only the axillary drain will be considered",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Prior axillary dissection (except prior sentinel node procedure)",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Prior axillary radiotherapy",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Psychiatric disorder precluding understanding of information on trial related topics, giving informed consent, filling out QoL forms",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Concurrent treatment with other experimental drugs or treatment in a clinical trial within 30 days prior to trial entry",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "42 year-old postmenopausal woman with infiltrating ductal breast carcinoma, HER2-positive and ER/PR negative. Lumpectomy was done with clear margins. Axillary sampling revealed 1 positive lymph node out of 12 sampled.",
  "_meta": {
    "topic_id": "25",
    "trial_id": "NCT02311543",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}